CD19 and neoplasm: Furthermore, we investigated their anti‐tumor potential in vivo, and studies using B16‐CD19 tumor‐bearing mice confirmed that CXCL13‐overexpression significantly enhanced CAR T cell‐mediated antitumor activity (Figure 2p), with a prolonged survival period (Figure 2q).